The use of taxanes in choriocarcinoma; a case report and review of the literature.
Both preclinical data and case reports support the use of taxanes for high-risk metastatic choriocarcinoma. We report the case of a 31-year-old with metastatic choriocarcinoma who required 3rd-line treatment with a paclitaxel-cisplatin-based regimen. She achieved a complete response and remains relapse-free 21 months after her last dose of chemotherapy. The literature suggests that paclitaxel contributes significantly to the treatment of choriocarcinoma and its use should be explored further. This is the first case report formally reporting its combination with cisplatin.